Clodagh M Ryan1,2,3,4, Kelly Wilton5, T Douglas Bradley5,6,7, Hisham Alshaer7. 1. Department of Medicine, University of Toronto, Toronto, ON, Canada. clodagh.ryan@uhn.ca. 2. University Health Network, Toronto, ON, Canada. clodagh.ryan@uhn.ca. 3. Sleep Research Laboratory of the Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada. clodagh.ryan@uhn.ca. 4. Centre for Sleep Health and Research, Toronto General Hospital, 9N-967 585 University Avenue, Toronto, ON, M5G2N2, Canada. clodagh.ryan@uhn.ca. 5. Department of Medicine, University of Toronto, Toronto, ON, Canada. 6. University Health Network, Toronto, ON, Canada. 7. Sleep Research Laboratory of the Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada.
Abstract
PURPOSE: Sleep apnea (SA) is highly prevalent in post-stroke patients. Due to physical disability and relative inaccessibility of polysomnography (PSG) to test for SA, patients with stroke frequently remain undiagnosed and untreated. Portable SA monitoring can facilitate at-home or in-hospital testing for SA. However, portable SA monitoring is not recommended in those with complex medical conditions, such as stroke, due to the lack of validation of portable monitoring in such patients. METHODS: The objective of our study was to test the accuracy and feasibility of a portable single-channel acoustic device, BresoDx™ for quantifying the apnea-hypopnea index (AHI) and diagnosing SA in a post-stroke population. Patients who recently suffered a stroke and were undergoing rehabilitation in a stroke rehabilitation unit (SRU) underwent testing with BresoDx both simultaneously during attended PSG and unattended on the SRU. RESULTS: We studied 23 stroke patients of whom 78% had SA (defined by AHI ≥15) on PSG. All of the patients tolerated the BresoDx. Using cutoff AHI of ≥15 by PSG to diagnose SA, BresoDx had sensitivity of 90.0%, specificity of 84.6%, and overall accuracy of 87.0% in the laboratory. CONCLUSIONS: This study demonstrates that BresoDx is well tolerated and feasible to use in the post-stroke population where it was found to have excellent positive and negative predictive values for the diagnosis of SA.
PURPOSE:Sleep apnea (SA) is highly prevalent in post-strokepatients. Due to physical disability and relative inaccessibility of polysomnography (PSG) to test for SA, patients with stroke frequently remain undiagnosed and untreated. Portable SA monitoring can facilitate at-home or in-hospital testing for SA. However, portable SA monitoring is not recommended in those with complex medical conditions, such as stroke, due to the lack of validation of portable monitoring in such patients. METHODS: The objective of our study was to test the accuracy and feasibility of a portable single-channel acoustic device, BresoDx™ for quantifying the apnea-hypopnea index (AHI) and diagnosing SA in a post-stroke population. Patients who recently suffered a stroke and were undergoing rehabilitation in a stroke rehabilitation unit (SRU) underwent testing with BresoDx both simultaneously during attended PSG and unattended on the SRU. RESULTS: We studied 23 strokepatients of whom 78% had SA (defined by AHI ≥15) on PSG. All of the patients tolerated the BresoDx. Using cutoff AHI of ≥15 by PSG to diagnose SA, BresoDx had sensitivity of 90.0%, specificity of 84.6%, and overall accuracy of 87.0% in the laboratory. CONCLUSIONS: This study demonstrates that BresoDx is well tolerated and feasible to use in the post-stroke population where it was found to have excellent positive and negative predictive values for the diagnosis of SA.
Entities:
Keywords:
Home sleep testing; Polygraphy; Sleep apnea; Stroke
Authors: Susan Redline; Gayane Yenokyan; Daniel J Gottlieb; Eyal Shahar; George T O'Connor; Helaine E Resnick; Marie Diener-West; Mark H Sanders; Philip A Wolf; Estella M Geraghty; Tauqeer Ali; Michael Lebowitz; Naresh M Punjabi Journal: Am J Respir Crit Care Med Date: 2010-03-25 Impact factor: 21.405
Authors: Justine A Aaronson; Coen A M van Bennekom; Winni F Hofman; Tijs van Bezeij; Joost G van den Aardweg; Erny Groet; Wytske A Kylstra; Ben Schmand Journal: Sleep Date: 2015-09-01 Impact factor: 5.849
Authors: Amir Qaseem; Paul Dallas; Douglas K Owens; Melissa Starkey; Jon-Erik C Holty; Paul Shekelle Journal: Ann Intern Med Date: 2014-08-05 Impact factor: 25.391
Authors: Michael Arzt; Terry Young; Laurel Finn; James B Skatrud; T Douglas Bradley Journal: Am J Respir Crit Care Med Date: 2005-09-01 Impact factor: 21.405
Authors: R Rola; H Jarosz; A Wierzbicka; A Wichniak; P Richter; D Ryglewicz; W Jernajczyk Journal: J Physiol Pharmacol Date: 2008-12 Impact factor: 3.011
Authors: Nancy A Collop; W McDowell Anderson; Brian Boehlecke; David Claman; Rochelle Goldberg; Daniel J Gottlieb; David Hudgel; Michael Sateia; Richard Schwab Journal: J Clin Sleep Med Date: 2007-12-15 Impact factor: 4.062
Authors: Michael T Saletu; Stefan T Kotzian; Angela Schwarzinger; Sandra Haider; Josef Spatt; Bernd Saletu Journal: J Clin Sleep Med Date: 2018-09-15 Impact factor: 4.062